NDAORALTABLET
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
ANTIVERT (meclizine hydrochloride) by R-Pharm US is h1 receptor. Approved for vertigo associated with diseases affecting the vestibular system in adults. First approved in 1957.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTIVERT (meclizine hydrochloride) is an oral H1 receptor antagonist approved in 1957 for treating vertigo associated with vestibular system diseases in adults. It works by blocking histamine receptors to reduce inner ear-related dizziness and balance disturbances. This is a well-established, first-line symptomatic therapy for vertigo management.
$0.002BPart D
LOE ApproachingAs LOE approaches, team focus shifts from growth to retention and cost management; expect smaller, efficiency-focused commercial teams.
Mechanism of Action
H1 receptor.
Career Relevance
Working on ANTIVERT offers limited career growth given its LOE-approaching status and minimal linked job openings (0 current roles). This is a stable, defensive assignment suited for professionals seeking predictable maintenance work rather than high-growth opportunities.
Brand Manager
Worked on ANTIVERT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.